Gunjan Bhardwaj is the Founder and CEO of the Innoplexus group. He was earlier with the Boston Consulting Group and before that the leader of the global business performance think-tank of Ernst & Young and a manager in the German practice with a solution focus on strategy and innovation.
He has led projects in strategy, analytics and technology for various clients in different parts of the world. Gunjan was also a partner, senior-editor and advisor for a prominent online innovation management journal and was a member of the scientific advisory board of a US based not for profit institute researching in complexity sciences in the healthcare industry.
Innoplexus is at the forefront of decision-making technology as the company works in data aggregation to provide to researchers, pharmaceutical companies, hospitals, and more. CEO and Founder Gunjan Bhardwaj, PhD, focuses his effort on managing exploratory and exploitative innovation. He recognizes the issue of security and data sharing in the EU and Innoplexus has taken advantage of the opportunity to make as much life science data available to his clients while aligning with GDPR. Find out in this next video about the three things his company does to ensure success.
The original article was published on Bizcast.
Pressemitteilung vom 08.01.2025 Die Amrit AG, ein Unternehmen der Partex Gruppe - einem führenden Anbieter von KI-Lösungen im Gesundheitswesen - gibt heute de...
Partnership aims to expand therapeutic potential of proprietary autotaxin inhibitor through AI-driven approach Frankfurt, Germany – Date – Partex, a leader in ...
Frankfurt, Germany, 3 rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce i...
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce its partnership wi...
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF Lifesciences, an established ...
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the results of a pilot project carr...
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, ...
January 02, 2024 - Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health data analysis, and AIO Studien gGmbH, ...
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV ...
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary medical exchange,...
Innoplexus wins Horizon Interactive Gold Award for Curia App
Read More